RE:RE:RE:How does a shares right plan help an investor in a takeover?
RGonlyfacts, I have no evidence to back up this claim, but you would be naive to think that a 45 mil market cap biotech, with a pending submission for FDA approval, is not at this moment being targeted for a lowball takeout. Blend in the long and sordid history of shareholder discontent and Bioniche is as ripe as the rotting banana on your countertop.